Inclusion Criteria

Inclusion Criteria for prostate cancer patients:

- localised prostate cancer, histologically proven

- Absence of metastases (M0) : normal bone scintigraphy

- Absence of radiological lymph node invasion (N0).

- Clinical Stage : T ≥ T1c-T2a and < T3b Or T1b or c with PSA ≤ 10 ng/ml . Or T1b or c
with Gleason ≥ 6

- PSA < 30 ng/ml.

- Signs and symptoms according to NCI/CTC v3.0 < grade 2

- ECOG Performance status ≤ 1

- Absence of hip prothesis

- Absence de endopenian stent

- Patient aged > 18 and < 80

- Patient affiliated with social security

- Written informed consent, dated and signed

Exclusion Criteria for prostate cancer patients:

- Antecedents of invasive cancer (unless if treated more than 5 years ago without
evolution) except basocellular carcinoma

- positive biopsy of seminal vesicle

- PSA ≥ 30 ng/ml for two successive dosages

- Previous pelvic irradiation

- Previous radical prostatectomy for cancer

- Patients with another systemic disease (cardiovascular, renal, hepatic, pulmonary
embolism, etc.) non stabilised or generalised sclerodermitis.

- Patients known to be HIV seropositive (no specific test is necessary for defining
eligibility)

- Known homozygote ATM (Ataxy telangiectasy) mutation

- Impossibility for a correct follow up (for social family or geographical reasons)

- Patients incapable of providing consent, protected majors, vulnerable persons

- Patients participating in other clinical trials

Inclusion Criteria for breast cancer patients:

- Breast Conservative surgery

- Non metastatic, M0

- negative surgical margins

- T1, T2; negative sentinel lymph node N0, N1 or N2.

- Signs and symptoms according to NCI/CTC v3.0 < grade 2

- Patient aged over 18 years and less than 60 or more than 60 with an indication for
boost irradiation.

- Patient affiliated with social security

- Written informed consent, dated and signed

Exclusion Criteria for breast cancer patients:

- Metastatic patients

- Bilateral breast cancer (concomitant or previous) except in situ

- T4 or N3 or treated by mastectomy

- Patients with chemotherapy or neoadjuvant hormonotherapy

- Patients with a previous other cancer within the last 5 years EXCEPT basocellular
carcinoma of the skin or in situ cancer of the uterus.

- Patients with another systemic disease (cardiovascular, renal, hepatic, pulmonary
embolism, etc.) non stabilised or generalised sclerodermia.

- Pregnant or breast feeding women

- Patients known to be HIV seropositive (no specific test is necessary for defining
eligibility)

- Known homozygote ATM (Ataxy telangiectasy) mutation

- Impossibility for a correct follow up (for social family or geographical reasons)

- Patients incapable of providing consent, protected majors, vulnerable persons

- Patients participating in other clinical trials